Navigation Links
Temporary Production Interruption at Allston Landing Manufacturing Facility Has No Impact on Aldurazyme
Date:6/16/2009

NOVATO, Calif., June 16 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that the temporary interruption of bulk production at Genzyme's Allston Landing manufacturing facility is not expected to have any impact on Aldurazyme supply or revenue to BioMarin or Genzyme. The last Aldurazyme fill at the Allston Landing facility was in September 2008. BioMarin has a total of approximately ten months of vialed inventory on hand, utilizes a second fill finish supplier and a third is expected to be qualified later this year. BioMarin manufactures Aldurazyme bulk material at its Novato facility and has adequate inventory in bulk and vialed form to meet expected ongoing Aldurazyme demand on a worldwide basis.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(R) (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is in clinical development for the treatment of PKU and GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase 1/2 clinical development for the treatment of MPS IVA. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

Forward-Looking Statement

This press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including, without limitation, statements about: the development of its product candidate PEG-PAL, the timing, design, conduct and expectations related to the PEG-PAL clinical trials, and expectations regarding filings with regulatory agencies. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: the results of current and planned clinical trials related to PEG-PAL; the content and timing of decisions by the U.S. Food and Drug Administration and other regulatory agencies, particularly with respect to PEG-PAL, and those factors detailed in BioMarin's filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption "Risk Factors" in BioMarin's 2008 Annual Report on Form 10-K. Stockholders are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.

BioMarin(R), Naglazyme(R) and Kuvan(R) are a registered trademarks of BioMarin Pharmaceutical Inc.

Aldurazyme(R) is a registered trademark of BioMarin/Genzyme LLC.

    Contact:

    Investors:                         Media:
    Eugenia Shen                       Susan Berg
    BioMarin Pharmaceutical Inc.       BioMarin Pharmaceutical Inc.
    (415) 506-6570                     (415) 506-6594


'/>"/>
SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. United Animal Nations Offers Financial Assistance Grants of up to $500 to Help Southern California Fire Victims Obtain Vet Care, Temporary Boarding for Pets
2. UniCare Announces Temporary Pharmacy Guidelines for Customers Affected by the California Wildfires
3. Homeless cells find temporary lodging -- and their demise
4. Aviva Belsky Promoted to Publisher of Contemporary Surgery
5. Some types of temporary neurological problems associated with increased risk for stroke, dementia
6. Temporary Amnesia, Confusion Raise Stroke, Dementia Risk
7. WuXi PharmaTech (NYSE: WX) Names Temporary Chairman of the Audit Committee
8. Statement by SEIU International President Andy Stern Regarding CNA Temporary Restraining Order
9. Temporary dentures improve patients smiles and overall health
10. Drug Effective for Temporary Sleep Disruptions
11. Unitemp Announces Unprecedented Temporary Staffing Services Guarantee
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... St. Petersburg, FL (PRWEB) , ... February 09, 2016 , ... Shark Finds ... of a new DRTV campaign with GRIP-DRY. , GRIP-DRY is a newly patented product that ... carts. Golfers who play in the wet and early morning dew or right after a ...
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... ... launched its newly redesigned website, federallabs.org . The site houses a wealth ... license available federal technologies through the process called technology transfer (T2). As a ...
(Date:2/8/2016)... ... 08, 2016 , ... Stephanie Hebert Insurance Agency, serving families ... new charity campaign. As part of their ongoing community involvement program, funds are ... that children deserve a voice, and in the spirit of neighbors helping neighbors ...
(Date:2/8/2016)... , ... February 08, 2016 , ... ... L top-load case packer for pouches, bags, and flow wrapped products at WestPack ... co-packers and specialty product manufacturers step up to semi-automatic or fully-automatic case packing ...
(Date:2/8/2016)... Hilton Head Island, SC (PRWEB) , ... February 08, 2016 , ... ... Head and surrounding areas with a vital new community enrichment program, has teamed up ... to local women and children suffering from intimate abuse. To support all those victimized ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... , Feb. 9, 2016  Johnson & Johnson (NYSE: ... Markets Global Healthcare Conference on Tuesday, Feb. 23, at ... Dominic Caruso , Vice President, Finance & Chief Financial ... will represent the Company in a session scheduled at ... --> www.investor.jnj.com . --> This ...
(Date:2/9/2016)... and HONG KONG , Feb. 9, ... Pedder , PhD, has joined Athenex as Vice President of ... Mr. Raymond Yeung , MSc, MBA has joined as Senior ... in Hong Kong . Simon ... team that I have known for a while. Coupled together ...
(Date:2/9/2016)... Feb. 9, 2016  Bluestar Silicones will promote its ... for long-term implant applications and announce certification of ... Manufacturing (MD&M) West Conference (Booth #1759), February 9-10, ... --> --> Available in 01 ... offer outstanding physical properties enabling our customers to ...
Breaking Medicine Technology: